Unione Europea - italiano - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Italia - italiano - Ministero della Salute

virbac - fipronil, piriproxifene - fipronil - 402 milligrammo (i); piriproxifene - 120.6 milligrammo (i), piriproxifene - 120.6 milligrammo (i); fipronil - 402 milligrammo (i), fipronil - 134 milligrammo (i); piriproxifene - 40.2 milligrammo (i), piriproxifene - 20.1 milligrammo (i); fipronil - 67 milligrammo (i), fipronil - 67 mg; piriproxifene - 20.1 mg, piriproxifene - 120.6 mg; fipronil - 402 mg, fipronil - 402 mg; piriproxifene - 120.6 mg, piriproxifene - 20.1 mg; fipronil - 67 mg, fipronil - 268 mg; piriproxifene - 80.4 mg, piriproxifene - 80.4 mg; fipronil - 268 mg, fipronil - 134 mg; piriproxifene - 40.2 mg - fipronil, combinations

Italia - italiano - Ministero della Salute

virbac - piriproxifene, fipronil - fipronil - 50 milligrammo (i); piriproxifene - 60 milligrammo (i), piriproxifene - 120 milligrammo (i); fipronil - 100 milligrammo (i), piriproxifene - 60 milligrammo (i); fipronil - 50 milligrammo (i), fipronil - 100 mg; piriproxifene - 120 mg, fipronil - 50 mg; piriproxifene - 60 mg, piriproxifene - 120 mg; fipronil - 100 mg - fipronil, combinations

Unione Europea - italiano - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampyra è indicato per il miglioramento della deambulazione nei pazienti adulti con sclerosi multipla con disabilità motoria (expanded disability status scale 4-7).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsule - fingolimodum 0,5 mg per fingolimodi hydrochloridum, mannitolum, magnesio stearas, kapselhülle: e 172 (giallo), e 171, gelatina, drucktinte: lacca, alcol isopropylicus, alcol butylicus, propylenglycolum, acqua purificata, ammoniae soluzione del 28 per cento, kalii hydroxidum, e 172 (nero), e 172 (giallo), e 171, dimeticonum per una piccola scatola. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, colore.: e 132, excipiens pro compresso haze. - traitement des patients adultes et des patients pédiatriques de 10 ans et plus présentant des formes récurrentes-rémittentes de sclérose en plaques (sep) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - cladribinum - compresse - cladribinum 10.00 mg, hydroxypropylbetadexum, sorbitolum 64.04 mg, magnesii stearas, pro compresso. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - fampridinum - retardtabletten - fampridinum 10 mg, cellulosum microcristallinum, hypromellosum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, titanii dioxidum, pro compresso obducto. - multiple sklerose - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.